| abstract |
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells, and methods for expressing the antibodies of this disclosure are also provided. Also provided are pharmaceutical compositions containing the immunoconjugate, bispecific molecule and the antibody of the present disclosure. The present disclosure also provides methods for detecting BTLA and methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies. |